
White paper

Reduction of contrast agent dose at low kV settings

Christian Canstein, MSc Johannes G. Korporaal, PhD

siemens-healthineers.us/computed-tomography







Introduction

Automated tube voltage selection enabled by Siemens Healthineers CARE kV* can be used for multiple clinical applications, with one of the most beneficial being contrast-enhanced scans with lower radiation dose but with consistent image quality.

This is an established method that is currently being used in clinical routine and that can help to reduce the radiation dose required. Overall, tube potentials between 70 and 100 kVp have been shown as most effective for clinical contrast CT examinations, depending on the specific situation.

With the advent of CT scanners with X-ray tubes powerful enough to produce high mA at low kV (e.g. SOMATOM go. Platform, SOMATOM Edge Plus, SOMATOM X.platform, SOMATOM Drive and SOMATOM Force, NAEOTOM Alpha), the same physical behavior of X-rays and iodine contrast agent can be used in clinical routine to reduce the amount of contrast agent instead of radiation dose.

This white paper briefly summarizes the scientific background and explains the principle of saving contrast agent dose instead of radiation dose.

Scientific background

The actual basis for low kV imaging is the mass attenuation coefficient, which is a property that depends on the chemical composition and density of a material and determines the specific absorption of X-ray beams by this material.

Figure 2 shows that for lower photon energies, the mass attenuation coefficient of iodine increases, whereas soft tissue is less energy-dependent. This means that with low kV imaging, and thus lower average photon energy, the iodine to soft tissue contrast in the CT image (in Hounsfield units, HU) will increase. This can be easily verified by scanning a static phantom with different iodine concentration samples at different tube voltages (Figure 3).

Due to the linear relationship between iodine concentration and enhancement, Figure 3 shows how much iodine can be saved if the attenuation is kept constant. For example, if an iodine enhancement of 300 HU is desired, the iodine concentration at 70 kV can be ~50% lower than the iodine concentration at 120 kV.




Figure 2. Mass attenuation coefficients for soft tissue and iodine at different photon energies. At lower energies, the difference in absorption between soft tissue and iodine increases, which results in a higher iodine contrast in the image. The K-edge of iodine leads to the spike visible at 33.2 keV. Data from NIST tables

^{*}Not available on the SOMATOM go.Now and SOMATOM go.Up




Figure 3. With static iodine phantoms, the increase in iodine enhancement (in HU) at a lower kV can be verified [data from iodine samples in 20 cm water phantom]. The arrow indicates how much iodine can potentially be saved in constant enhancement when going from 120 to 70 kV.

When comparing the relative iodine enhancement between all different kVs from 70 to 150 kV with each other, it is possible to calculate the potential change in iodine concentration with a decrease in kV while yielding the same iodine enhancement in HU (Figure 4).

reference kV		new kV	[lodine] Change mg/mL
120	\rightarrow	120	0
120	\rightarrow	110	-0.10
120	\rightarrow	100	-0.20
120	\rightarrow	90	-0.30
120	\rightarrow	80	-0.40
120	\rightarrow	70	-0.49

New/Alternative kV

		70 kV	80 kV	90 kV	100 kV	110 kV	120 kV	130 kV	140 kV	150 kV
Reference kV	70 kV	1	+0.18	+0.37	+0.58	+0.77	+0.97	+1.14	+1.36	+1.54
	80 kV	-0.15	1	+0.16	+0.33	+0.50	+0.67	+0.81	+0.99	+1.15
	90 kV	-0.27	-0.14	1	+0.15	+0.29	+0.44	+0.56	+0.72	+0.85
	100 kV	-0.37	-0.25	-0.13	1	+0.12	+0.25	+0.36	+0.49	+0.61
	110 kV	-0.44	-0.33	-0.23	-0.11	1	+0.11	+0.21	+0.33	+0.44
	120 kV	-0.49	-0.40	-0.30	-0.20	-0.10	1	+0.09	+0.19	+0.29
	130 kV	-0.53	-0.45	-0.36	-0.26	-0.17	-0.08	1	+0.10	+0.19
	140 kV	-0.58	-0.50	-0.42	-0.33	-0.25	-0.16	-0.09	1	+0.08
	150 kV	-0.61	-0.53	-0.46	-0.38	-0.30	-0.22	-0.16	-0.07	1

Figure 4. Table displaying the relative change in iodine concentration necessary when either lowering or increasing the tube voltage for constant HU enhancement from a vial of iodine within a 30 cm of water phantom. (Assuming a 1 mg/mL value of iodine as the baseline for each kV.)

Data from phantom experiments with static iodine concentration, patient results may vary depending on patient size.

120 kV, 80 kV, 120 mL contrast 40 mL contrast

Figure 1. Clinical examples of two patients scanned with a default 120 kV protocol with 120 mL of contrast agent (left) and with a reduced kV protocol (80 kV) with only 40 mL on SOMATOM Force. Courtesy of Radiologie Karlsruhe Karlstrasse and Universitätsklinikum Mannheim, Germany

The principle of saving contrast agent dose

The main aim of Siemens Healthineers CARE kV* is to maintain image quality when changing the kV, with image quality defined in terms of the contrast-to-noise ratio (CNR). Since it is directly dependent on enhancement, the CNR increases for lower kVs if radiation and iodine dose are fixed (Figure 5). This fact can be utilized to either save radiation dose or iodine dose while keeping the CNR constant; however, it is dependent on patient size. Before explaining the principle of saving contrast agent dose, the principle of saving radiation dose will briefly be reviewed.

Saving radiation dose

The starting point for saving radiation dose is the assumption that the same injection, protocol (amount, concentration and timing) of the reference protocol (R) would be used for all kVs, which inherently leads to an increase in iodine attenuation with decreasing kV.

As the iodine contrast increases, noise can be allowed to increase by the same extent to maintain the CNR. Then for each kV level, the respective tube current (mAs) required to reach the desired noise level is determined, as well as the corresponding radiation dose (CTDIvol). Finally, the kV level yielding the lowest radiation dose that can be achieved by the system will be chosen.

This methodology is schematically illustrated in Figure 6a.

Saving contrast agent dose

If the aim is to reduce the contrast agent dose instead of the radiation dose, the same steps need to be performed as when saving radiation dose. However, these four steps should be taken in the opposite order, as described on the next page and as illustrated in Figure 6b.





Figure 5. CNR increases for lower kV settings at fixed ${\rm CTDI}_{\rm vol}$ and fixed iodine dose.

^{*}Not available on the SOMATOM go.Now and SOMATOM go.Up


Figure 6. Low kV imaging at constant contrast-to-noise ratio: a) Principle of saving radiation b) Principle of saving contrast agent dose R denotes the reference protocol.

Aim: Constant image quality (CNR) for all tube voltages




Save radiation dose (CARE kV)


Step 1 Starting point: Contrast agent dose is fixed




Step 2 How much iodine enhancement do you get?



Step 3 How much noise is needed to obtain required CNR?




Which kV has the lowest radiation dose **Step 4** for the required noise?




Save contrast agent dose


Starting point: Radiation dose is fixed




How much image noise do you get?



How much iodine enhancement is needed to obtain required CNR?



Which kV has the lowest contrast agent dose for the required iodine enhancement?











Vectron

Straton MX Sigma

Athlon

Chronon

Step 1

When reducing the contrast agent dose (Figure 6b), the new starting point is the radiation dose (CTDIvol) of the reference protocol (R), which should be kept constant for all kV levels. This can be achieved by adjusting the tube current (mA). Until now this step had not been possible in clinical routine due to certain technical limitations of CT systems: the X-ray tubes of existing CT systems were not powerful enough to produce sufficient tube currents at low kV settings to maintain the CTDIvol of the reference protocol. Consequently, measures to save iodine dose were only feasible in pediatric or very thin patients. However, with the Vectron™ tube with vastly increased tube power at low kVs (up to 2 x 120 kW, up to 2 x 1,300 mA at 70-90 kV, as integrated in NAEOTOM Alpha, SOMATOM Force, and SOMATOM X.platform) it is now possible to scan even obese patients at low tube voltages with sufficiently high mA and thus offer the possibility of contrast agent dose reduction. SOMATOM Drive with the Straton MX Sigma tube provides 2 x 100 kW and 2 x 650 mA at 70 kV, and 2 x 750 mA at 80 and 90 kV. SOMATOM Edge Plus with the Straton MX Sigma tube provides 100 kW and 650 mA at 70 kV, and 750 mA at 80 and 90 kV. SOMATOM go. Top and go. All with the Athlon tube provides 75 kW and 825 mA at 70 and 80 kV and 800 mA at 90 kV. SOMATOM go.Up and go.Now with the Chronon tube provides 32 kW and 400 mA at 80 kV.

Step 2

For each kV and mAs combination, the resulting image noise can be calculated using the topogram of the patient. It is important to stress that a specific radiation dose will not result in the same image noise at the different tube voltages. Particularly at a lower kV, the image noise will be higher for a given CTDI_{vol}. Although this effect is small, it reduces the contrast agent reduction potential that would be possible if one were to consider only the increased iodine enhancement at a lower kV.

Step 3

With the expected image noise calculated in step 2, the iodine enhancement that is required to preserve the desired CNR can be calculated for each kV.

Step 4

If the required iodine enhancement is known, the corresponding contrast agent dose at each kV can be calculated. Based on this, the tube voltage setting that requires the lowest iodine contrast agent dose to reach this enhancement level can be selected.

This principle works on every CT scanner; however, for meaningful savings of contrast agent dose a significant decrease in the kV is required (Figure 4). In the past, it has not been possible to keep the dose constant at all kV levels, as the X-ray tubes were not powerful enough to produce sufficient tube current (mA) at low kV levels. New X-ray tubes powering the new generation of scanners, like NAEOTOM Alpha, SOMATOM Force, SOMATOM Drive, SOMATOM X.platform, SOMATOM Edge Plus and SOMATOM go. Platform, now have sufficient power to fulfill this condition (Figure 7).

An additional technical enhancement that enables the success of this principle are the availability of iterative reconstruction methods (such as ADMIRE and SAFIRE) and integrated circuit detectors (Stellar detector) which help to reduce image noise at low kV scans and therefore allow for a diagnostic image quality even at low kV settings.

Low kV contrast CT scanning is feasible in clinical routine and, depending on user preferences, it can be used directly to reduce either radiation or iodine dose.

It is possible to use low kV imaging to save both radiation and iodine dose at the same time; however, the configuration of a suitable protocol is not easy and the reduction potential for both radiation and iodine is significantly less compared to the two methods described above.



The increase in iodine enhancement at lower kV can be utilized to reduce the contrast agent dose, while maintaining the image quality (CNR) at a given radiation dose.




Figure 7: Maximum tube output at different kVs: With conventional tubes, sufficiently high mAs output at low kVs is only possible for pediatric examinations (black arrows). New CT tube generations, however, can overcome this limitation. This enables a significant reduction in the kV, not only in protocols for children, but also for large adult scans (gray arrow).

70 kV, 70 mL contrast




Figure 8: Clinical example of a patient scanned with a suggested 70 kV protocol with 70 mL of contrast agent on SOMATOM Edge Plus.

80 kV, 30 mL contrast



Figure 9: Clinical example of a TAVR patient scanned with a 80 kV protocol with 30 mL of contrast agent on SOMATOM Force.

Saving contrast agent in clinical practice

If one changes from a reference scan protocol to a low kV protocol and one decides to reduce the contrast agent dose, the contrast injection protocol must be adapted to reduce the iodine load.

The easiest way to adapt the iodine load seems to be a reduction of the contrast volume without changing any other injection parameters.


However, a reduction in contrast volume leads to a shorter injection duration and, thus, to significant changes in the contrast enhancement over time: peak enhancement occurs earlier, requiring adaptation of the scan delay, and scan timing becomes more critical because of a narrower enhancement curve.

To avoid these changes in scan timing, the preferred and most robust strategy to achieve contrast dose reduction is to keep the injection duration constant while reducing the iodine delivery rate (IDR).

Reduction of the IDR can be accomplished by lowering the iodine concentration and/or the volume and injection flow rate, which will lead to identical temporal enhancement curves for reference and low kV protocols.

As previously demonstrated in a pre-clinical animal study (Figure 8), peak width, peak height, and peak time remain the same with a reduction of the IDR. More practical details, for instance about setting the CTDIvol of reference protocols for lower kVs and adaptation of the bolus tracking parameters, can be found in the "How-to" guide, which provides step-by-step instructions for clinical application.

120 kV, 64 mL at 5.0 mL/s, 300 mgl/mL



70 kV, 32 mL at 2.5 mL/s, 300 mgl/mL




Figure 8: An animal study in pigs demonstrated that an identical temporal enhancement curve for the 120 kV reference protocol (left) and 70 kV protocol (right) can be obtained with constant injection duration and adapted IDR, while saving 50% in contrast agent.

Data courtesy of Lell et al.

References

Scientific Publications:

Siegel MJ, Schmidt B, Bradley D, Suess C, Hildebolt C. Radiation dose and image quality in pediatric CT: effect of technical factors and phantom size and shape. Radiology 2004; 233(2):515–522.

Sigal-Cinqualbre AB, Hennequin R, Abada HT, Chen X, Paul JF. Low-kilovoltage multidetector row chest CT in adults: feasibility and effect on image quality and iodine dose. Radiology 2004; 231(1):169–174.

Nakayama Y, Awai K, Funama Y et al. Abdominal CT with low tube voltage: preliminary observations about radiation dose, contrast enhancement, image quality, and noise. Radiology 2005; 237(3): 945–951.

Fleischmann D, Kamaya A. *Optimal vascular and parenchymal contrast enhancement: the current state of the art.* Radiol Clin North Am. 2009 Jan;47(1):13-26.

Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology 2010; 256:32-61.

Gnannt R, Winklehner A, Eberli D, Knuth A, Frauenfelder T, Alkadhi H. Automated tube potential selection for standard chest and abdominal CT in follow-up patients with testicular cancer: comparison with fixed tube potential. Eur Radiol. 2012 Sep;22(9):1937-45.

Sodickson A, Weiss M. Effects of patient size on radiation dose reduction and image quality in low-kVp CT pulmonary angiography performed with reduced IV contrast dose. Emerg Radiol. 2012 Oct;19(5):437-45.

Hough DM, Yu L, Shiung MM, Carter RE, Leng S, Fidler JL, Huprich JE, Yondal DY, McCollough CH, Fletcher JG. *Individualization of Abdominopelvic CT Protocols With Lower Tube Voltage to Reduce IV Contrast Dose or Radiation Dose*. AJR 2013; 201:147-153.

Azzalini L, Abbara S, Ghoshhajra BB. *Ultra-low contrast computed tomographic angiography (CTA) with 20-mL total dose for transcatheter aortic valve implantation (TAVI) planning.* J Comput Assist Tomogr. 2014 Jan-Feb;38(1):105-9.

Lell MM, Jost G, Korporaal JG et al. *Optimizing contrast media injection protocols in state-of-the art CTA*. Invest Radiol. 2015 (in press), DOI: 10.1097/RLI.00000000000119

Lu GM, Luo S, Meinel FG, McQuiston AD, Zhou CS, Kong X, Zhao YE, Zheng L, Schoepf UJ, Zhang LJ. *High-pitch computed tomography pulmonary angiography with iterative reconstruction at 80 kVp and 20 mL contrast agent volume*. Eur Radiol. 2014; 24(12):3260-3268

Meinel FG, Canstein C, Schoepf UJ, Sedlmaier M, Schmidt B, Harris BS, Flohr TG, De Cecco CN. *Image quality and radiation dose of low tube voltage 3rd generation dual-source coronary CT angiography in obese patients: a phantom study.* Eur Radiol 2014 Jul;24(7):1643-50

Meyer M, Haubenreisser H, Schoepf UJ, Vliegenthart R, Leidecker C, Allmendinger T, Lehmann R, Sudarski S, Borggrefe M, Schoenberg SO, Henzler T. Closing in on the K Edge: Coronary CT Angiography at 100, 80, and 70 kV-Initial Comparison of a Second-versus a Third-Generation Dual-Source CT System. Radiology 2014; 273(2):373-382

Szucs-Farkas Z, Christe A, Megyeri B, Rohacek M, Vock P, Nagy EV, Heverhagen JT, Schindera ST. *Diagnostic accuracy of computed tomography pulmonary angiography with reduced radiation and contrast material dose: a prospective randomized clinical trial*. Invest Radiol. 2014 Apr;49(4):201-8.

Websites:

http://www.nist.gov/pml/data/xraycoef

https://www.healthcare.siemens.com/medical-imaging/low-dose/order-guide-to-low-dose

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with Al-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care.

Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion.

Further information is available at www.siemens-healthineers.com.

The outcomes and statements provided by customers of Siemens Healthineers are unique to each customer's setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, and level of service/technology adoption), there can be no guarantee that others will achieve the same results.

On account of certain regional limitations of sales rights and service availability, we cannot guarantee that all products included in this brochure are available through the Siemens Healthineers sales organization worldwide. Availability and packaging may vary by country and is subject to change without prior notice. Some/All of the features and products described herein may not be available in the United States.

The information in this document contains general technical descriptions of specifications and options as well as standard and optional features, which do not always have to be present in individual cases.

Siemens Healthineers reserves the right to modify the design, packaging, specifications, and options described herein without prior notice. For the most current information, please contact your local sales representative from Siemens Healthineers.

Note: Any technical data contained in this document may vary within defined tolerances. Original images always lose a certain amount of detail when reproduced.

Siemens Healthineers Headquarters

Siemens Healthcare GmbH Henkestr. 127 91052 Erlangen, Germany siemens-healthineers.com USA

Siemens Medical Solutions USA, Inc. Healthcare 40 Liberty Boulevard Malvern, PA 19355-9998, USA siemens-healthineers.us